Los Angeles, CA - A recent study conducted by Cedars-Sinai Cancer has uncovered a fascinating link between the loss of the Y chromosome in men and the body's ability to combat cancer. Published in Nature, the research reveals that the loss of the Y chromosome allows cancer cells, particularly in aggressive bladder cancer, to evade the immune system. Paradoxically, this loss also makes the tumors more susceptible to immune checkpoint inhibitor treatment, a standard therapy for bladder cancer.
The study, led by Dr. Dan Theodorescu, director of Cedars-Sinai Cancer, demonstrates a groundbreaking connection between the loss of the Y chromosome and the immune system's response to cancer. By observing aggressive bladder cancer cells, the researchers discovered that the absence of the Y chromosome enables these cells to grow rapidly and avoid detection by the immune system.
Previous studies have shown that various cancer types, including 10%-40% of bladder cancers, exhibit loss of the Y chromosome in men. This phenomenon has also been associated with heart disease and Alzheimer's disease.
The Y chromosome contains genetic information crucial for certain genes. Building on this knowledge, the investigators developed a scoring system to assess the extent of Y chromosome loss in bladder cancer tumors.
The research team analyzed data from two groups of men: one group underwent bladder removal surgery without immune checkpoint inhibitor treatment, while the other participated in a clinical trial and received immune checkpoint inhibitors. The findings revealed that patients with loss of the Y chromosome had a worse prognosis in the first group, but significantly improved overall survival rates in the latter group.
To delve deeper into the underlying mechanisms, the investigators conducted experiments using laboratory mice. They grew bladder cancer cells in a controlled environment where the cells were shielded from immune cells, as well as in mice lacking a specific type of immune cell known as T-cells. In both settings, tumors with and without the Y chromosome exhibited similar growth rates.
However, in mice with intact immune systems, tumors lacking the Y chromosome grew at a much faster rate than tumors with an intact Y chromosome. This finding suggests that the presence of the immune system is essential for the observed effect of Y chromosome loss on bladder cancer growth.
Theodorescu explains, "These results imply that when cells lose the Y chromosome, they exhaust T-cells. And without T-cells to fight the cancer, the tumor grows aggressively."
Based on their observations in human patients and laboratory mice, the research team also determined that tumors without the Y chromosome, although more aggressive, displayed increased vulnerability and responsiveness to immune checkpoint inhibitor therapy. This treatment, a cornerstone of current bladder cancer therapies, reinvigorates T-cell function and allows the immune system to combat the cancer.
Dr. Hany Abdel-Hafiz, co-first author of the study, highlights the significance of this finding, stating, "Fortunately, this aggressive cancer has an Achilles’ heel, in that it is more sensitive than cancers with an intact Y chromosome to immune checkpoint inhibitors."
Theodorescu suggests that the loss of the Y chromosome may also contribute to the aggressiveness of prostate cancers, although preliminary data supporting this hypothesis has not yet been published.
The research provides valuable insights into the adaptive strategies employed by tumor cells to evade the immune system and survive in multiple organs. Shlomo Melmed, executive vice president of Academic Affairs and dean of the Medical Faculty at Cedars-Sinai, acknowledges the importance of these findings in enhancing our understanding of cancer biology and potentially revolutionizing cancer treatment.
Further investigation is necessary to unravel the genetic mechanisms linking Y chromosome loss to T-cell exhaustion. If scientists can decipher these mechanisms, they may be able to prevent T-cell exhaustion altogether, thereby improving patient outcomes.
Although women do not possess a Y chromosome, the implications of this study extend to both sexes. The Y chromosome contains related genes, known as paralogue genes, which are present on the X chromosome. Understanding the role of these genes in both men and women requires further exploration.
Dr. Theodorescu concludes, "Awareness of the significance of Y chromosome loss will stimulate discussions about the importance of considering sex as a variable in all scientific research in human biology. The fundamental new knowledge we provide here may explain why certain cancers are worse in either men or women and how best to treat them. It also illustrates that the Y chromosome does more than determine human biologic sex.”
The study, led by Dr. Dan Theodorescu, director of Cedars-Sinai Cancer, demonstrates a groundbreaking connection between the loss of the Y chromosome and the immune system's response to cancer. By observing aggressive bladder cancer cells, the researchers discovered that the absence of the Y chromosome enables these cells to grow rapidly and avoid detection by the immune system.
Previous studies have shown that various cancer types, including 10%-40% of bladder cancers, exhibit loss of the Y chromosome in men. This phenomenon has also been associated with heart disease and Alzheimer's disease.
The Y chromosome contains genetic information crucial for certain genes. Building on this knowledge, the investigators developed a scoring system to assess the extent of Y chromosome loss in bladder cancer tumors.
The research team analyzed data from two groups of men: one group underwent bladder removal surgery without immune checkpoint inhibitor treatment, while the other participated in a clinical trial and received immune checkpoint inhibitors. The findings revealed that patients with loss of the Y chromosome had a worse prognosis in the first group, but significantly improved overall survival rates in the latter group.
To delve deeper into the underlying mechanisms, the investigators conducted experiments using laboratory mice. They grew bladder cancer cells in a controlled environment where the cells were shielded from immune cells, as well as in mice lacking a specific type of immune cell known as T-cells. In both settings, tumors with and without the Y chromosome exhibited similar growth rates.
However, in mice with intact immune systems, tumors lacking the Y chromosome grew at a much faster rate than tumors with an intact Y chromosome. This finding suggests that the presence of the immune system is essential for the observed effect of Y chromosome loss on bladder cancer growth.
Theodorescu explains, "These results imply that when cells lose the Y chromosome, they exhaust T-cells. And without T-cells to fight the cancer, the tumor grows aggressively."
Based on their observations in human patients and laboratory mice, the research team also determined that tumors without the Y chromosome, although more aggressive, displayed increased vulnerability and responsiveness to immune checkpoint inhibitor therapy. This treatment, a cornerstone of current bladder cancer therapies, reinvigorates T-cell function and allows the immune system to combat the cancer.
Dr. Hany Abdel-Hafiz, co-first author of the study, highlights the significance of this finding, stating, "Fortunately, this aggressive cancer has an Achilles’ heel, in that it is more sensitive than cancers with an intact Y chromosome to immune checkpoint inhibitors."
Theodorescu suggests that the loss of the Y chromosome may also contribute to the aggressiveness of prostate cancers, although preliminary data supporting this hypothesis has not yet been published.
The research provides valuable insights into the adaptive strategies employed by tumor cells to evade the immune system and survive in multiple organs. Shlomo Melmed, executive vice president of Academic Affairs and dean of the Medical Faculty at Cedars-Sinai, acknowledges the importance of these findings in enhancing our understanding of cancer biology and potentially revolutionizing cancer treatment.
Further investigation is necessary to unravel the genetic mechanisms linking Y chromosome loss to T-cell exhaustion. If scientists can decipher these mechanisms, they may be able to prevent T-cell exhaustion altogether, thereby improving patient outcomes.
Although women do not possess a Y chromosome, the implications of this study extend to both sexes. The Y chromosome contains related genes, known as paralogue genes, which are present on the X chromosome. Understanding the role of these genes in both men and women requires further exploration.
Dr. Theodorescu concludes, "Awareness of the significance of Y chromosome loss will stimulate discussions about the importance of considering sex as a variable in all scientific research in human biology. The fundamental new knowledge we provide here may explain why certain cancers are worse in either men or women and how best to treat them. It also illustrates that the Y chromosome does more than determine human biologic sex.”